Cadonilimab Injection

Regorafenib

Huikai Li, MD

Xihao Zhang, Doctor

Xihao zhang, Doctor

To evaluate the efficacy and safety of Cadonilimab Injection in combination with Regorafenib in the treatment of intermediate to advanced biliary systemic tumours that has failed at least one prior systemic therapy

An open, single-arm, single-centre clinical study evaluating Cadonilimab Injection in combination with Regorafenib for the treatment of biliary systemic tumours that have failed at least one prior systemic therapy

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

An Open, Single-arm, Single-centre Clinical Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours That Have Failed at Least One Prior Systemic Therapy

Defined as proportion of patients who have a best response of CR or PR

OS is defined as the time from date of neoadjuvant treatment start to the date of death from any cause or to the date of last follow-up if patients are alive. If a patient is alive by the time of final analysis, the patient will be censored at the last follow-up date.

Defined as the time from enrollment to disease progression or death (whichever occurs first)

Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours	NCT05644392	Advanced Biliar...	Cadonilimab Inj... Regorafenib	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours	NCT05644392	Advanced Biliar...	Cadonilimab Inj... Regorafenib	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital

Spots Global Cancer Trial Database for advanced biliary systemic tumours that has failed at least one prior systemic therapy